Evidence map›Paper›PMID 38500290›Full record

ArticleAnti-cancer agents in medicinal chemistry2024

Bee Venom Toxic Effect on MDA-MB-231 Breast Cancer Cells and

Yáskara Veruska Ribeiro Barros, Amanda Onduras de Andrade, Larissa Pereira Dantas da Silva, Lucas Aleixo Leal Pedroza, Iverson Conrado Bezerra, Iago Dillion Lima Cavalcanti, Mariane Cajuba de Britto Lira Nogueira, Kristiana Cerqueira Mousinho, Angelo Roberto Antoniolli, Luiz Carlos Alves and 5 more

Abstract read
PubMed Publisher
In one paragraph

Article in Anti-cancer agents in medicinal chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 1 country.

Yáskara Veruska Ribeiro BarrosHealth Sciences Post-Graduate Program, Federal University of Sergipe, São Cristóvão, Brazil.
Amanda Onduras de AndradeKeizo Asami Institute, iLIKA, Federal University of Pernambuco, Recife, Brazil.
Larissa Pereira Dantas da SilvaPostgraduate Program in Biological Science, Federal University of Pernambuco, Pernambuco, Recife, Brazil.
Lucas Aleixo Leal PedrozaKeizo Asami Institute, iLIKA, Federal University of Pernambuco, Recife, Brazil.
Iverson Conrado BezerraKeizo Asami Institute, iLIKA, Federal University of Pernambuco, Recife, Brazil.
Iago Dillion Lima CavalcantiKeizo Asami Institute, iLIKA, Federal University of Pernambuco, Recife, Brazil.
Mariane Cajuba de Britto Lira NogueiraKeizo Asami Institute, iLIKA, Federal University of Pernambuco, Recife, Brazil.
Kristiana Cerqueira MousinhoCESMAC University Center, Maceio, Alagoas, Brazil.
Angelo Roberto AntoniolliDepartment of Physiology, Federal University of Sergipe, São Cristóvão, Sergipe, Brazil.
Luiz Carlos AlvesKeizo Asami Institute, iLIKA, Federal University of Pernambuco, Recife, Brazil.
José Luiz de Lima FilhoKeizo Asami Institute, iLIKA, Federal University of Pernambuco, Recife, Brazil.
Alexandre Varão MouraMS4Life Laboratory of Mass Spectrometry, Health Sciences Postgraduate Program, São Francisco University, Bragança Paulista, São Paulo 12916-900, Brazil.
Álex Aparecido Rosini SilvaMS4Life Laboratory of Mass Spectrometry, Health Sciences Postgraduate Program, São Francisco University, Bragança Paulista, São Paulo 12916-900, Brazil.
Andréia de Melo PorcariMS4Life Laboratory of Mass Spectrometry, Health Sciences Postgraduate Program, São Francisco University, Bragança Paulista, São Paulo 12916-900, Brazil.
Priscila GubertKeizo Asami Institute, iLIKA, Federal University of Pernambuco, Recife, Brazil.ORCID 0000-0002-3598-8050
Universidade Federal de Pernambuco · BRUniversidade São Francisco · BRUniversidade Federal de Sergipe · BRCentro Universitário Cesmac · BR

Funding

National Council for Scientific and Technological Development (CNPQ) CNPq/409246/2018-2National Institute of Science and Technology on Molecular Science (INCT-CiMol) 406804/2022-2ODCDC CDC HHS P40 OD010440
6 · The paper itself

Abstract

introductionBee venom has therapeutics and pharmacological properties. Further toxicological studies on animal models are necessary due to the severe allergic reactions caused by this product.

methodHere,

resultsBee venom did not increase the expression of SOD-3, but it enhanced DAF-16 translocation from the cytoplasm to the nucleus.

conclusionThus, due to its potential toxic effect and induction of allergic reactions, using bee venom as a therapeutic approach has been limited. The development of controlled-release drug strategies to improve this natural product's efficacy and safety should be intensified.

Indexed as

Antineoplastic AgentsBee VenomsCaenorhabditis elegansAnimalsBreast NeoplasmsCell ProliferationCell SurvivalDose-Response Relationship, DrugDrug Screening Assays, AntitumorFemaleHumansMolecular StructureStructure-Activity RelationshipAntineoplastic AgentsBee VenomsApis melliferaApitoxinbreast cancerCaenorhabiditis elegans.cytotoxicitymetabolomic

Identifiers

PMID38500290
OpenAlexW4392965933

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.